Compared with a share repurchase, a one-off special dividend:
is administratively simpler to arrange,
returns surplus cash directly to shareholders (all shareholders receive cash, ownership proportions are unchanged).
Answers: D and E

In CIMA F3's coverage of short-term financing, commercial paper (CP) is identified as a very cost-effective funding source for large, high-credit-quality companies. CP is an unsecured, short-term promissory note, typically issued for periods up to 270 days, making it ideal for a 6-month funding need. Because it is issued directly into the money markets by strong credits, the interest cost is usually lower than overdrafts or short- term bank loans, which include a bank's margin.
The scenario states that the company is large, listed, has an "excellent credit rating", minimal default risk and already has a commercial paper programme. This matches the textbook profile of a company for which CP is the cheapest source of short-term borrowing.
Treasury bills (C) are issued by governments, not companies, so they are an investment vehicle, not a borrowing method here. Bank overdrafts (A) are flexible but generally expensive and better for fluctuating day-to-day needs. A 6-month term loan (B) tends to involve higher arrangement fees and interest margins than CP. Therefore, option D is the most cost-effective choice.

Post-acquisition, Company X's annual post-tax cash flow = 8m in perpetuity.
Cost of equity = 10%.
Combined value after acquisition:
Vcombined=80.10=80 millionV_{\text{combined}} = \frac{8}{0.10} = 80\ \text{million}Vcombined=0.
108=80 million
Pre-acquisition total value:
VX+VY=50+20=70 millionV_X + V_Y = 50 + 20 = 70\ \text{million}VX+VY=50+20=70 million Synergy value:
Synergy=80#70=10 million\text{Synergy} = 80 - 70 = 10\ \text{million}Synergy=80#70=10 million

This question examines the appropriateness of debt financing instruments in the context of a high-risk, growth- oriented pharmaceutical company, which is a classic scenario discussed within CIMA F3 under Financing Decisions, Risk and Capital Structure, and Hybrid Finance.
Company P operates in a sector characterised by long development cycles, high uncertainty, and intangible asset bases. Its value derives primarily from human capital and intellectual property rather than tangible fixed assets. According to CIMA F3 study guidance, such firms face significant difficulty raising conventional straight debt, as lenders typically require stable cash flows and asset security. Furthermore, the company's existing cash flows are only sufficient for operational needs, not major R&D expenditure, increasing perceived credit risk.
A convertible bond is explicitly highlighted in CIMA F3 as a suitable financing instrument for companies with high growth potential but limited current cash flows. Convertible bonds combine features of debt and equity, offering investors downside protection through fixed interest payments while providing upside potential through conversion into equity if the company succeeds. This reduces the required coupon rate (4% in this case), easing short-term cash flow pressure, which is crucial for Company P during the development phase of the new drug.
Importantly, the doctors who own and manage Company P wish to retain control, a key strategic constraint.
Convertible bonds delay equity dilution until conversion occurs and only if the company performs well. This aligns with F3 principles that hybrid instruments are appropriate when firms wish to balance financing needs with control considerations.
The alternative options are unsuitable:
* Eurobonds and conventional bonds (Options A and B) require strong credit standing and asset backing.
* Commercial paper (Option C) is short-term, unsecured, and inappropriate for long-term R&D funding.
Therefore, consistent with CIMA F3 guidance on risk-adjusted financing strategy, the most appropriate choice is the convertible bond.